Caplin Point Laboratories Ltd Stock Analysis

BSE: 524742 | NSE: CAPLIPOINT | Pharmaceuticals & Drugs | Mid Cap

BSE Share Price 02-Dec-2022 18:01
760.55 5.25 (0.70%)

DeciZen - Make an Informed Decision on Caplin Point Lab

Overall Rating

1. Quality

2. Valuation

Somewhat overvalued

3. Price Trend

Caplin Point Lab Price Chart

P/E Ratio (CD) :
Market Cap :
5,765 Cr.
52-wk low :
52-wk high :
Bole Toh?

1. Is Caplin Point Laboratories Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Caplin Point Laboratories Ltd is a average quality company.

2. Is Caplin Point Laboratories Ltd undervalued or overvalued?

The key valuation ratios of Caplin Point Laboratories Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.

3. Is Caplin Point Laboratories Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Caplin Point Laboratories Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Caplin Point Lab:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Caplin Point Laboratories Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

ROCE % 36.9%50.3%54.2%42.5%52.7%47.8%33.9%24.1%21.9%21.4%-
Value Creation Index

Growth Parameters

Growth Parameters Colour Code Guide

Sales 1271732523184025406498631,0611,2691,371
YoY Gr. Rt. %-36.3%45.5%26.4%26.2%34.4%20.2%33.1%23%19.6%-
YoY Gr. Rt. %-77%53.2%48.5%46.9%50.2%20%16.1%22.9%20.9%-
BVPS (₹) 5.27.711.821.729.747.778114.2144.9184.8222.4
Adj Net Profit 15.82842.963.693.5141169196241292331
Cash Flow from Ops. 3259.849.956.567.666.583.444.7269337-
Debt/CF from Ops.


CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 29.1%25.9%25.1%19.6%
Adj EPS 38.2%25.5%19.9%20.9%
BVPS 48.644.133.327.5
Share Price 48.5% 3.1% 33.9% -6.1%

Key Financial Parameters

Performance Ratio Colour Code Guide

Return on Equity % 41.153.455.343.15347.733.824.822.621.821.4
Op. Profit Mgn % 19.622.724.828.
Net Profit Mgn % 12.416.217.12023.3262622.723.623.624.1
Debt to Equity 0.10.1000000000
Working Cap Days 956147716795133176197211387
Cash Conv. Cycle -50-57-49-68-51-193311211592313

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 25.08%

Net Profit is growing at healthy rate in last 3 years 19.93%

Sales growth is good in last 4 quarters at 18.54%

Return on Equity has declined versus last 3 years average to 21.40%

Latest Financials - Caplin Point Laboratories Ltd.

Standalone Consolidated
TTM EPS (₹) 24.9 43.6
TTM Sales (₹ Cr.) 494 1,371
BVPS (₹.) 137.1 222.4
Reserves (₹ Cr.) 1,024 1,671
P/BV 5.55 3.42
PE 30.52 17.43
From the Market
52 Week Low / High (₹) 626.30 / 888.45
All Time Low / High (₹) 0.18 / 1034.00
Market Cap (₹ Cr.) 5,765
Equity (₹ Cr.) 15.2
Face Value (₹) 2
Industry PE 37.8

Management X-Ray of Caplin Point Lab :

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Caplin Point Lab

Adj EPS (Rs.)
Sales (Cr.)
ROE (%)
ROCE (%)


Caplin Point Laboratories Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Caplin Point Lab on 02-Dec-2022 18:01 is : 760.5.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 02-Dec-2022 18:01 the market cap of Caplin Point Lab stood at ₹ 5,765.
The latest PE ratio of Caplin Point Lab as of 02-Dec-2022 18:01 is 30.52.
The latest PB ratio of Caplin Point Lab as of 02-Dec-2022 18:01 is 5.55
The 52-week high of Caplin Point Lab is ₹ 888.5 and the 52-week low is ₹ 626.3.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue / sales of Caplin Point Lab is ₹ 493.5 ( Cr.) .

About Caplin Point Laboratories Ltd

Caplin Point Laboratories was established in 1990 to manufacture a range of ointments, creams and other external applications. The Company was listed in 1994; the IPO proceeds were deployed in a manufacturing facility in Pondicherry. The promoters exposed their lives to physical risk when they ventured into war-affected countries more than two decades ago. The Company ventured into the emerging markets of West Africa, Latin America and The Caribbean to market finished formulations. The Company’s asset-light marketing business model has helped generate the resources to build world-class infrastructure.

The success of Caplin Point is primarily attributed to its unique business model. Starting of as an SME, Caplin Point decided at an early stage that the conventional style of exports would mean diminishing margins and reduced opportunities for expansion, and had taken the unique step of creating last mile logistical solutions for its exclusive distributors across Latin America and various parts of Africa. This way, Caplin Point is able to generate adequate revenue and cash flow to remain debt-free with benchmark receivables, and also continue to invest in state of the art manufacturing facilities from internal accruals. One of the main reasons for the success can be attributed to the wide range of products offered across diverse geographies.

Business area of the company

Caplin Point is the mid-sized company in India’s pharmaceutical sector to be engaged in the manufacture of APIs, finished formulations, research & development, clinical research, frontend generic presence in Latin America, brand marketing in Francophone Africa and an USFDA approved injectable facility.


  • Liquid Injections
  • Lyophilised Injections
  • Opthalmic
  • Tablets
  • Liquid Orals
  • Capsule
  • Softgel Capsules
  • Suppositories & Ovules
  • Powder for Injection
  • Dry syrup
  • Topicals
  • Liquid Injections
  • Inhalers
  • Ophthalmic
  • IV Infusion
  • Lyophilised Products
  • Branded Products
  • Dermo Cosmetics

Awards and recognitions

  • 2014: Forbes Asia Best under a Billion Award - 2014.
  • 2015: Forbes Asia Best under a Billion Award - 2015.
  • 2016: Forbes Asia Best under a Billion Award - 2016.
  • 2017: Nanayam Vikatan’s Gold Phoenix Award to Mr. C C Paarthipan.
  • 2017: Financial express CFO Awards 2017 (Second Rank).
  • 2017: IPF’s industrial Excellance Award.
  • 2018: The Economic Times - Family Business of the year Award.
  • 2018: Pharmexcil Outstanding Exports Award 2018.
  • 2018: The Economic Times Award for Excellence in Business Performance.
  • 2019: Empowering India Awards 2019 in Pharmaceutical, Healthcare and Bio-Technology Segment.
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now